Peps
What is VIP?
Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.
Biological role or research focus
Vascular, inflammatory, and respiratory research.
This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
Names you may encounter
Vasoactive intestinal peptide · Aviptadil
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Vasoactive intestinal peptide; aviptadil drug name
- Research focus
- Vascular, inflammatory, and respiratory research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Biology & proposed mechanism
VIP signaling has several physiological effects. Biological plausibility should be separated from the measured response to a specific preparation in a particular disease.
Research context & identity
The featured publication evaluates critical illness due to COVID-19. It does not resolve chronic gastrointestinal or immune conditions.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2023
TESICO aviptadil trial
What did this publication test, and what did it find?
- Population / model
- 461 people with COVID-19-associated respiratory failure.
- Study design
- Randomized placebo-controlled trial with a 90-day ordinal clinical outcome.
- Main finding
- The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different.
- Limits & context
- This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
Human randomized trial · 2022
Aviptadil · earlier respiratory-failure trial
How should the earlier favorable survival signal be read?
- Population / model
- 196 patients with critical COVID-19 respiratory failure at ten U.S. hospitals.
- Study design
- Multicenter placebo comparison with a 60-day endpoint; participants randomized 2:1.
- Main finding
- The primary outcome—alive without respiratory failure—did not reach statistical significance: OR 1.6 (95% CI 0.86–3.11). A separate survival result favored aviptadil: OR 2.0 (95% CI 1.1–3.9).
- How to read it
- A favorable separate outcome does not turn a missed primary endpoint into a positive primary trial.
- Limits & context
- Secondary and subgroup signals need confirmation. Read this beside the later TESICO trial; differences in design and populations prevent selective use of favorable headlines. Neither trial establishes general wellness use of VIP.
Source: Aviptadil · earlier respiratory-failure trial · 2022 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Critical-care treatment requires close monitoring. The lack of efficacy on the primary outcome must be weighed alongside treatment burdens and adverse events.
Evidence boundaries
This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
9 matching video records · 3 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Peptide Of The Week
Peptide of the Week: Epithalon & Glutathione – Longevity, Sleep & Detox ↗
Captions indexed · Automatic matches need review
Peptide Of The Week
Telehealth vs Research Peptides: The Truth Nobody Tells You | Peptide of the Week Q&A #61 ↗
Captions indexed · Automatic matches need review
Trevor Kruder
Episode 17: Klotho & FLGR242 Explained: The Science Behind the Next Generation of Peptides ↗
Captions indexed · Automatic matches need review
Biohackingturkey
VIP Peptidi Nedir? 60 Saniyede Temel Bilgiler 🧬 ↗
Title match · Captions not indexed
Biohackingturkey
VIP Peptidi Nedir? Hücrelerinizi Gençleştiren Gizli Güç! ↗
Title match · Captions not indexed
Fouad Abiad Media
IS SAM SULEK THE NEWEST HOSSTILE ATHLETE?! | HOSSTILE VIP VISIT | Fouad Abiad, Ben Chow, Paul Lauzon ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
VIP (Vasoactive Intestinal Peptide) (5mg)
BioLongevity Labs · Vendor-labeled research use only
$74.97
Listed in stock · Snapshot 2026-10-04
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
VIP (10 mg)
PSPeptides · Vendor-labeled research use only
$74.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Did TESICO prove that VIP improves COVID-19 outcomes?
- What material, population, and route were actually studied?
- This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did TESICO prove that VIP improves COVID-19 outcomes?
No. The primary comparison and the mortality comparison did not reach statistical significance.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.